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A B S T R A C T   
Critical for transcription initiation and bulky lesion DNA repair, TFIIH provides an exemplary system to connect 
molecular mechanisms to biological outcomes due to its strong genetic links to different specific human diseases. 
Recent advances in structural and computational biology provide a unique opportunity to re-examine biologi-
cally relevant molecular structures and develop possible mechanistic insights for the large dynamic TFIIH 
complex. TFIIH presents many puzzles involving how its two SF2 helicase family enzymes, XPB and XPD, 
function in transcription initiation and repair: how do they initiate transcription, detect and verify DNA damage, 
select the damaged strand for incision, coordinate repair with transcription and cell cycle through Cdk- 
activating-kinase (CAK) signaling, and result in very different specific human diseases associated with cancer, 
aging, and development from single missense mutations? By joining analyses of breakthrough cryo-electron 
microscopy (cryo-EM) structures and advanced computation with data from biochemistry and human ge-
netics, we develop unified concepts and molecular level understanding for TFIIH functions with a focus on 
structural mechanisms. We provocatively consider that TFIIH may have first evolved from evolutionary pressure 
for TCR to resolve arrested transcription blocks to DNA replication and later added its key roles in transcription 
initiation and global DNA repair. We anticipate that this level of mechanistic information will have significant 
impact on thinking about TFIIH, laying a robust foundation suitable to develop new paradigms for DNA tran-
scription initiation and repair along with insights into disease prevention, susceptibility, diagnosis and 
interventions.   
1. Introduction 
TFIIH is an amazingly sophisticated and exemplary protein machine 
required for three key pathways in the cell: transcription initiation, 
global genome nucleotide excision repair (GG-NER) and transcription- 
coupled nucleotide excision repair (TC-NER) [1]. Depending on 
context, its composition changes from a core of seven subunits (XPD, 
XPB, p62, p52, p44, p34, p8) to ten subunits, by adding in a three 
subunit Cdk-activating-kinase (CAK) module (CDK7, cyclin H, MAT1). It 
utilizes three enzymatic activities at different pathway steps: 1) a 
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serine/threonine kinase (CDK7), 2) a double strand (ds)DNA translocase 
(XPB), and 3) a 5′–3′ helicase (XPD) [2]. An SF2 helicase family enzyme 
XPB was originally identified as a helicase with limited in vitro helicase 
activity. As we note in detail below, recent XPB structures and 
biochemistry is more consistent with XPB being a translocase than a 
helicase, so we herein refer to XPB as a translocase. Furthermore, TFIIH 
regulates other enzymes including the structure-specific nucleases 
XPF-ERCC1 and XPG in NER, and RNA polymerase II (Pol II) in tran-
scription initiation. Mutations in TFIIH are linked to three human dis-
eases, xeroderma pigmentosum (XP), Cockayne syndrome (CS) and 
trichothiodystrophy, which display distinct phenotypes [2]. The XPD 
subunit of TFIIH contains a [4Fe-4S] cluster, making it a member of a 
special group of DNA-binding [4Fe-4S]-containing proteins that in-
cludes DNA polymerases, helicases, primases, and glycosylases [3]. 
Overall, TFIIH is an essential, highly coordinated molecular machine 
whose precise orchestration of its functions and molecular mechanisms 
are only now being unveiled. 
In transcription initiation, TFIIH opens the promoter DNA for Pol II 
and facilitates promoter release (reviewed in [4–6]). TFIIH is recruited 
as a ten-subunit complex (core plus kinase module) to Pol II preinitiation 
complex (PIC) by TFIIE (Fig. 1) [7]. Although TFIIH has two SF2 helicase 
family enzymes, only XPB (encoded by the excision repair 
cross-complementation group 3 gene, ERCC3) translocase activity is 
required to open up the promoter for Pol II to begin transcription [8]. 
When bound to TFIIH, CDK7 of the CAK kinase module phosphorylates 
the Pol II C-terminus to allow promoter escape. The free form of CAK 
activates the cell cycle CDKs, and the CAK-XPD complex regulates cell 
cycle progression in mitosis [9,10]. 
The TFIIH core (7 subunits excluding the kinase module) is essential 
for NER (reviewed in [2,11,12]), the only major DNA repair pathway for 
photolesions induced by ultraviolet radiation (UV) in placental mam-
mals [13]. Strong sunlight can induce ~100,000 UV lesions per exposed 
cell per hour [14]), making NER a critical pathway. In fact, many TFIIH 
associated proteins were named through elegant genetic complemen-
tation experiments for xeroderma pigmentosum (XP), a rare inherited 
skin cancer prone disorder characterized by a heightened sensitivity to 
UV DNA damage [15–17]. These key genetic experiments make TFIIH an 
exemplary system not only for characterizing the interplay of repair with 
transcription and cell cycle, but furthermore, for linking molecular 
mechanisms to eventual prediction of biological outcomes from single 
site mutations [2,18–20]. 
Importantly, in addition to UV irradiation, NER repairs bulky DNA 
damage formed by environmental agents and cancer chemotherapeutic 
drugs. It operates through a multi-step process: lesion recognition, 
opening of the DNA around the lesion, lesion verification, excision of the 
lesion as part of an oligonucleotide, repair synthesis to replace the 
removed DNA and ligation to seal the nick (Fig. 2). GG-NER and TC-NER 
are two distinct repair sub-pathways and differ in their damage recog-
nition. GG-NER is activated by recognition of destabilization of the DNA 
helix induced by the lesion, TC-NER by a stalled RNA polymerase II (Pol 
II) during transcription [21]. In GG-NER, the primary protein to recog-
nize bulky DNA lesions, XPC-RAD23B, binds to DNA opposite to the 
lesion, which displays single strand (ss)DNA character, and unwinds the 
duplex to form a small bubble of ~ 2–3 nucleotides (nts) (step 1). Recent 
single molecule studies have shown that XPC-RAD23B may undergo 
diffusion around the lesions site until it fully engages with the lesion [22, 
23]. Centrin, a third member of the XPC complex, enhances XPC activity 
but is not essential in reconstituted NER reactions [24]. Another NER 
protein, the UV–DNA damage binding (UV–DDB) complex (not shown) 
is required for recognition of certain lesions, especially in the context of 
chromatin, reviewed in [25]. Once this small bubble has formed, 
XPC-RAD23B recruits TFIIH (step 2), which uses XPB translocase and 
XPD (encoded by ERCC2 gene) helicase activities to further open the 
duplex to create a bubble of 23− 25 nts (step 3). Unlike for transcription 
initiation, both XPB and XPD ATPase activities are required for NER 
[26]. 
The XPA and RPA scaffolding proteins bind to this opened bubble 
[27]. XPA acts in damage verification for both GG-NER and TC-NER, and 
helps recruit the structure specific endonuclease XPF (ERCC4). So, if 
XPA levels are substantially decreased, it can become a rate-limiting 
factor for NER [28]. RPA serves to protect the ssDNA on the undam-
aged strand (step 4). XPF-ERCC1 and then XPG incise the dsDNA close 
to the 5′ and 3′ ss/dsDNA junctions of the DNA bubble, respectively; the 
lesion is thus removed as part of a ~25− 27mer excised oligonucleotide 
[29–31]. The dual incision step is a highly coordinated process, and 
current models suggest that ERCC1-XPF makes the first incision (step 6), 
followed by partial repair synthesis (step 7), incision 3′ to the lesion by 
XPG (step 8) and completion of repair synthesis and ligation. DNA Pol δ 
(and possibly other polymerases), RFC, PCNA, and DNA ligase I or IIIα 
are involved in these later NER steps (step 10). 
XPC-RAD23B and UV-DDB are not involved in the TC-NER sub- 
pathway, and bulky DNA damage in transcribing strands is instead 
efficiently recognized by the lesion stalling elongating RNA Pol Il 
(reviewed in [11,21]). This triggers ubiquitylation of RNA Pol II at a 
single residue (K1268) and initiation of TC-NER [32,33]. CSB is then 
recruited, followed by CSA and its associated DDB1-CUL4 ubiquitin 
Fig. 1. Pathway for Transcription Pre-
Initiation Complex (PIC) and Initiation. After 
TFIID, TFIIA, TFIIB recruit Pol II, TFIIE is 
recruited and in turn, recruits TFIIH. TFIIE is 
positioned as a molecular latch, locking down 
TFIIH and limiting overall TFIIH flexibility. The 
XPB translocase will negatively supercoil the 
initiator element (INR) DNA to open it for Pol 
II. Pol II C-terminal domain (CTD) phosphory-
lation by the CAK kinase module in the ten- 
subunit TFIIH will promote Pol II release from 
the INR.   
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Fig. 2. Pathway for Nucleotide Excision 
Repair (NER). 0) Bulky DNA lesions are 
repaired by NER. (1) In global repair, XPC- 
RAD23B recognizes the lesion (red X). (2) 
Helicase complex machinery (TFIIH, XPG, XPA) 
is recruited by XPC. (3) XPB subunit of TFIIH 
translocates along the DNA, leading to forma-
tion of ssDNA. (4) XPC-RAD23B, whose primary 
interface is to dsDNA, is released. RPA binds 
and protects ssDNA on the undamaged strand. 
(5). XPD captures the ssDNA and uses its 
ATPase activity to find the lesion. (6) XPF 
makes the first cut (arrow) in the dsDNA 5′ to 
the lesion. (7) Polδ, RFC, and PCNA load onto 
DNA 5′ to the lesion and start DNA synthesis 
replacing the damaged region. (8) XPG incises 
the dsDNA 3′ to the lesion (arrow). (9) TFIIH 
and XPG leave with the damaged strand. (10) 
To complete repair, DNA ends are rejoined by 
DNA ligase.   
Fig. 3. TFIIH functional conformational changes enable differentactivities. Structures are overlaid based on the XPB chain and shown as ribbons. Upper panels 
show TFIIH A) in a transcription PIC complex with promoter DNA, B) in solution and DNA-free, and C) in an initial NER complex with XPA and Y-DNA. All models 
shown are based on cryoEM density, and subunits or subunit regions not detectable in density are not shown. Thus, PIC and solution TFIIH models are missing CAK/ 
cyclin H subunits present in the original sample, while the TFIIH-XPA-DNA model is missing p62. The PIC and solution models are additionally based on our 
integrative computational methods. Pol II and transcription factors are colored gray. Insets highlight molecular rigging character of TFIIE and p62. Lower panels 
show only the DNA, XPB, XPD, and XPA chains. In transcription initiation, XPD is shifted away from the DNA (marked by small arrow and X). In NER, XPD rotates 
towards and binds the ssDNA (marked by large arrow). Scale and perspective are maintained in all panels. 
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ligase complex [33,34]. CSA and CSB together promote the association 
of the UVSSA protein, which is in turn ubiquitylated and required for 
TFIIH to join the TC-NER complex [33,34]. Although the fate of ubiq-
uitylated RNA polymerase during TC-NER is not fully understood, cur-
rent models suggest that it is removed from the damaged strand, 
allowing for TFIIH to fully engage the lesion. A striking similarity be-
tween GG-NER and TC-NER is that XPC and UVSSA share an interaction 
surface in the pleckstrin homology (PH) domain of the p62 subunit of 
TFIIH, suggesting that the two pathways at least partially share a 
mechanism for the engagement of TFIIH with the lesion site [35,36]. 
Given that XPA, RPA, XPG and ERCC1-XPF are also required for TC-NER, 
and that the size of the excised oligonucleotide is similar, following 
engagement of TFIIH, the mechanism for TC-NER repair is thought to 
closely resemble GG-NER. Interestingly, an added component for NER in 
lower eukaryotes - the ATL1 (alkyltransferase-like 1) protein – has been 
shown to regulate choice between GG-NER and TC-NER on the basis of 
how tightly it binds to alkylated DNA, which in turn appears to depend 
on the size of the lesion [37,38]. 
The mechanism for how TFIIH opens dsDNA remains an enigma. 
While both XPD and XPB have homology to the SF2 helicase family and 
display limited helicase activity, their unwinding and opening of dsDNA 
is more consistent with a model where they function as ssDNA and 
dsDNA translocases whose activities lead to strand separation, respec-
tively. Building upon crystal structures of TFIIH subunits, breakthrough 
cryo-electron microscopy (cryo-EM) structures of TFIIH complexes have 
provided informative glimpses of TFIIH alone, and as it would appear in 
transcription initiation and in NER (Fig. 3) [39–44]. Excellent reviews 
cover the details of these structures, along with insights into specific 
activities and structural mechanisms [4–645–47]. 
Here we build upon knowledge of TFIIH evolution, genetics, and 
structures, combining them to address how TFIIH works, i.e. the un-
derlying mechanisms for its biological functions. Our premise is that 
while genetics and biochemistry provide deep insights into what the 
individual TFIIH subunits do, structures can help us to understand how 
they do it. Importantly, as these proteins have been perfecting their 
activities for three billion years, they have much to teach us about how 
they accomplish their amazing efficiency and specificity. This informa-
tion in turn provides clear direction for future research and better un-
derstanding of NER biology and medicine. 
We consider the following critical questions. How does TFIIH work? 
What are the differences between TFIIH mechanisms in transcription 
initiation versus DNA repair? What can we learn from the genetics and 
disease mutations? This perspective builds upon the field’s current 
knowledge and highlights what we know, points we infer, and mecha-
nisms that remain to be explored. Since biology works by the bottom-up 
self-assembly of proteins from sequence building blocks to develop 
complex functionalities, we will try to place integrated information and 
models into context of sequence-based atomic models. Our objective is 
that these atomic-level models stimulate ideas and discussions, identify 
important unanswered questions, and suggest future experimental di-
rections for the scientific community. 
2. Overall architecture of TFIIH 
To begin this discussion, we first introduce the overall architecture of 
TFIIH and then the three “types” of TFIIH structure (Fig. 3). A) TFIIH (10 
subunits) as part of the Pol II PIC in transcription initiation [40,42,43, 
48,49]; B) TFIIH (10 subunits) alone [39,43,44]; C) TFIIH (7 subunits) 
with XPA and Y-DNA [41]. Supplemental Movie 1 highlights confor-
mational changes between the three types of TFIIH. 
TFIIH has a central core of 7 subunits (Fig. 3C) [50–54]. XPB [55,56] 
and XPD [57–59] each have RecA/Rad51 helicase domains 1 and 2 
(HD1 and HD2). XPD has an additional two domains, an [4Fe-4S] cluster 
domain (FeS) and an arch domain whose sequences are interwoven with 
HD1. XPB has poor helicase activity in vitro and is likely a dsDNA 
translocase that results in strand separation, in concert with other 
proteins. XPD has limited helicase activity requiring 5′ ssDNA overhangs 
and is implicated in verifying the presence of a chemical modification 
after initial recognition of helix destabilization by XPC [57–63]. The five 
other subunits have no known enzymatic activity and are named on the 
basis of their approximate molecular weight: p8, p34, p44, p52, and 
p62. With the exception of p62, these subunits are globular and 
assemble into a horseshoe shape with XPB and XPD on the ends. p62 is 
an extended, non-globular protein that stretches out like molecular 
rigging, connecting 5 of the 7 subunits (XPD, XPB, p44, p34, and p52). 
Interestingly, its path switches between p52 and XPB depending on if 
TFIIH is free in solution or in a transcription initiation complex, 
respectively. The p44 subunit is surrounded by p34, XPD, p62, but also 
stretches out N- and C-terminal helices to contact XPB, fully consistent 
with its critical role in TFIIH assembly. The kinase module adds another 
three subunits in transcription initiation: CDK7, Cyclin H and MAT1. 
Unlike CDK7 and Cyclin H which are thought to be flexibly tethered to 
the core and thus have not been modeled in the cryo-EM structures, the 
MAT1 subunit acts as a brace between XPB and XPD and likely reduces 
XPD domain mobility [64]. 
Analysis of the three TFIIH conformations (Fig. 3) reveals how evo-
lution has structurally optimized TFIIH to avoid potential problems 
arising from its roles in both transcription initiation and NER, which 
might occur if TFIIH inadvertently switches from transcription initiation 
to NER and the mistakenly initiated repair process causes ssDNA breaks. 
Similarly, TFIIH can be toxic to the cell as it could randomly bind and 
open up dsDNA. Thus, TFIIH uses multiple controls to regulate XPD 
activity. 1) The XPB-bound dsDNA path is away from XPD. In transcription 
initiation, the configuration of TFIIH results in the dsDNA path leading 
away from XPD and towards Pol II (Fig. 3 lower panels). A similar 
dsDNA trajectory can be extrapolated from the XPB position in the so-
lution structure. If the dsDNA base stacking is disrupted as observed 
from XPC-RAD23B insertion at the DNA lesion in NER [65], the dsDNA 
could be bent to the extent needed to redirect its path towards XPD. This 
suggests that an external protein is required to license XPD activity. 2) 
XPB is positioned away from XPD. XPB is physically separated from XPD 
in free TFIIH and in transcription initiation complexes, compared to the 
TFIIH-XPA-DNA NER complex (Fig. 3 lower panels). Both MAT1 (in the 
CAK subunit) and XPA span XPB and XPD, but with opposite conse-
quences. The long MAT1 helix is reminiscent of a spanner that separates 
XPB and XPD, while the arms of XPA, with MAT1 removed, appear to 
facilitate bringing XPB and XPD together. 3) Blocking of XPD helicase 
sites. In the free TFIIH and PIC structures, the XPD ssDNA-binding groove 
is blocked by p62 and XPB, and the XPD ATP-binding site is capped by 
p62, likely inhibiting both DNA binding and helicase activity of XPD 
(Fig. 4A) [39,43]. Thus, the seemingly meandering path of p62 has real 
functional implications in free TFIIH and PIC complexes. In the 
TFIIH-XPA-DNA NER structure, p62 is not modeled in the density [41]. 
However, it has been proposed that some of the unassigned cryo-EM 
density is p62 aligned above the XPD ssDNA binding groove [66]. The 
strong enhancement of XPD helicase activity by XPA makes XPA the 
likely candidate for moving p62 and XPB out of the XPD functional sites 
[41,60]. 4) Regulation of XPD mobility. The action of SF2 helicase family 
members requires domains to move relative to each other. MAT1 in-
teracts with the ARCH domain in XPD, which will reduce inter-domain 
motion in XPD, consistent with the reported reduction in XPD helicase 
activity [64]. We did not observe any such negative controls for XPB. 
Taken together, these observations illustrate that TFIIH quaternary 
structure is designed to be transcription initiation-ready, but 
repair-inhibited. 
In contrast to the organization of TFIIH in the PIC and free structures, 
the TFIIH-XPA-DNA structure unveils the repair-ready conformation. In 
this structure, XPD has shifted unexpectedly by ~80 Å to be next to XPB 
and in position to bind the first ssDNA nts at the ss/dsDNA junction 
(Fig. 4B). Other subunits in the core TFIIH horseshoe also shifted and 
rotated to accommodate this arrangement. The “hole” in the TFIIH 
center, first speculated as a place for DNA binding, closes like a finger 
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trap in the TFIIH-XPA-DNA structure and in fact may be required for this 
rearrangement to occur (See Supplemental Movie). It will be interesting 
if differentially exposed surfaces on TFIIH subunits mediate protein- 
protein interactions in subsequent stages of NER. For example, XPB 
residues 315–328 are in the interface with XPD in the solution structure 
but are exposed in the TFIIH-XPA-DNA structure. Could these residues 
be important for XPB interaction with RPA and/or XPF? In the following 
we consider mechanisms for how XPB and XPD work. 
3. How does XPB work as a dsDNA translocase to open dsDNA? 
XPB was historically identified as a 3′–5′ helicase, even though it 
didn’t work as a helicase in classical helicase assays that measure gen-
eration of ssDNA from dsDNA. It was also drawn as binding to ssDNA. In 
fact, as noted years ago [67,68] and recently confirmed [69], XPB is not 
a typical helicase but a translocase that moves along dsDNA and un-
winds dsDNA, as a complex with other proteins. Working on duplex 
DNA, XPB binds both strands and does not show polarity. 
Given this reassignment of XPB as a dsDNA translocase, it is worth 
revisiting conclusions from initial analyses of XPB as a “helicase” and 
from studies that use mutations that disrupt XPB’s “helicase” activity. In 
particular, we re-examined the interpretation that XPB helicase activity 
is not required for NER [26]. The authors showed that mutants within 
one XPB helicase motif caused partial reduction in transcription initia-
tion and no apparent impact on NER, from which it was concluded that 
XPB “helicase” activity is not required for NER, only the ATPase activity. 
With the hindsight provided by XPB structures with DNA [41,42], we 
found that the “helicase” residues, mutated in that study, do not directly 
contact DNA and predict that the mutants likely reduce, but do not 
eliminate XPB domain movements and translocation. If XPB trans-
location was not rate limiting in their NER assay, reduced activity could 
not have been detected, putting back into question if XPB translocase 
activity is required or not in NER. Mutations designed from the currently 
available structures should enable generation of DNA binding-defective 
XPB variants that will make it possible to distinguish whether the 
required ATPase activity is needed in NER for the translocase activity or 
for allosteric communication. In the meantime, we hypothesize that XPB 
translocase is involved in NER. 
So, how does the XPB translocase lead to unwound DNA? We propose 
two complementary mechanisms. 
With XPB and XPD somewhat fixed relative to each other, it is 
important to change the perspective for thinking about the action of 
these enzymes. Classically, translocases and helicases move relative to 
DNA, which is held stationary. This makes sense in a chromosomal 
context as the DNA would be less mobile than the protein. With respect 
to the lesion-containing strand, XPB is a dsDNA translocase that moves 
3′–5′ and XPD a helicase that moves 5′–3′. However, XPB and XPD are 
held in relatively fixed positions in TFIIH complexes; they cannot move 
in opposite directions on the same DNA while remaining roughly at the 
same distance from each other. If the DNA is moving, then this apparent 
paradox is resolved. This is also applicable in transcription initiation 
(see discussion below). So, to understand our proposed mechanisms, we 
change the perspective to DNA being moved by a mostly fixed XPB and 
XPD. 
The first mechanism is applicable for both transcription initiation 
and NER. XPB acts by twisting dsDNA inducing negative supercoiling, 
thereby opening the duplex [43,48] (Fig. 5). We first describe features of 
this mechanism for the PIC in transcription initiation. 1) XPB binds in 
the minor groove, as observed in TFIIH structures with DNA. 2). We 
assume that XPB remains in the minor groove as it translocates, analo-
gous to a unicycle (XPB) on a track (DNA minor groove). 3) We further 
assume that XPB is fixed, which means that the DNA moves. Because 
DNA is helical and XPB stays in the minor groove, the DNA spirals to-
wards Pol II and the other PIC factors. 4) XPB is locked to Pol II and the 
PIC by TFIIE and by subunits of TFIIH such as MAT1 and p62 [43]. 
Therefore, XPB and Pol II do not move relative to each other. 5) The DNA 
bound in the PIC is fixed and cannot rotate. 6) Because the PIC side of the 
DNA is fixed, the spiraling DNA moving away from XPB cannot relieve 
tension and becomes negatively supercoiled [67,69,70]. 7) Negative 
supercoiling causes DNA unpairing [71]. 
In GG-NER where there is no Pol II, other NER proteins prevent the 
DNA from freely rotating as XPB translocates: XPC-RAD23B, XPA, p62, 
and XPD are all candidates. The requirement is that they prevent DNA 
rotation on the other side of the targeted region, while being fixed 
relative to TFIIH. Early on in NER, it is likely that XPC-RAD23B prevents 
Fig. 4. TFIIH moves from transcription initiation-ready, repair inhibited 
to repair ready. A) TFIIH is repair inhibited. p62 and XPB block XPD ssDNA 
binding path; and p62 caps the ATP-binding site; and MAT1 prevents XPD 
domain motions. Overlay of apoTFIIH (protein ribbon, PDB:6O9M) with ssDNA 
(TFIIH-XPA-DNA, PDB:6O9M), and BeADP (spheres, DinG, PDB:6FWS). XPD 
HD2 domain was used for the overlay. B) Conformation changes between so-
lution, DNA-free XPB-XPD (apoTFIIH) and DNA-bound XPB-XPD (TFIIH-XPA- 
DNA) subcomplexes (overlay on XPB). MAT1, a part of CAK subcomplex, is 
bound between XPB and XPD to restrict XPD from binding to DNA. To enable 
NER, XPA is recruited to bind XPB and dsDNA. XPA facilitates XPB unwinding 
through separating pin Trp175, disengages CAK subcomplex to allow XPD to 
shift ~80 Å to load on unwound ssDNA, and holds XPD close to 5′ end of the 
junction to start lesion scanning to 3′ end on the damaged strand. 
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rotation of DNA; XPC binds to duplex DNA non-specifically through the 
TGD-BHD1 domains and begins unwinding the DNA by inserting its 
BHD2 and BHD3 loops into the DNA duplex at the lesion site [65] 
(Fig. 5B) [65,72]. XPC insertion and opening of the duplex DNA is 
energetically linked to DNA bending, a feature that can help redirect the 
dsDNA towards XPD, as in Fig. 3C. XPC has at least two interaction 
surfaces with TFIIH –one at the C-terminus believed to be involved in 
binding XPB and the other, a region at the N-terminus that binds the p62 
pleckstrin homology (PH) domain [35,73]. We propose that the multiple 
interaction sites of XPC with DNA, p62 and XPB could anchor XPB, 
thereby preventing free rotation of the DNA. Consistent with this idea, 
DNA opening is increased upon addition of TFIIH and ATP to XPC [74]. 
This opening of the DNA could be sufficient to allow XPD to bind to 
ssDNA (preventing rotation and as part of TFIIH, being fixed to XPB). In 
the TFIIH-XPA-DNA structure, XPA inserted its Trp175 on a beta hairpin 
at the ss/dsDNA junction and would thereby prevent rotation, while 
being fixed against TFIIH (Fig. 3C). The XPD arch domain, p44, and p62 
are also implicated in DNA binding and are therefore candidates to 
prevent dsDNA rotation [64,66]. 
As the bubble is progressively opened and other proteins are 
recruited, XPC is released and would no longer contribute to negative 
supercoiling. XPG recruitment is coincident with XPC displacement 
[75–78], either due to competition or conformational changes that 
eliminate the XPC binding interface to TFIIH. Could enhancement of 
XPD helicase activity by XPG and disruption of XPC dsDNA binding 
interfaces by negative supercoiling and unwinding of the dsDNA 
partially contribute? Coming back to the question of the DNA tension 
from negative supercoiling, the previously XPC-occupied DNA is posi-
tioned to be clamped by XPD on the ssDNA and XPG on the dsDNA. 
Another possibility is that XPB translocase activity, perhaps after bind-
ing of XPA, induces additional supercoiling that together with the XPD 
translocation toward the lesion leads to dissociation of XPC-RAD23B. 
The second mechanism is specific to NER and incorporates the de-
parture of the CAK, in particular MAT1 which spans XPB and XPD. We 
propose that XPA has an important role. In the following, we describe 
the critical features of this mechanism. 1) In the TFIIH-XPA-DNA 
structure [79], Trp175 in XPA is positioned to serve as a “strand-sepa-
ration pin” (Fig. 5B) [41]. Thus, as XPB translocates, the dsDNA is split 
by the pin, as observed in many helicases [80–83]. 2) XPA disengages 
the CAK kinase module from TFIIH [84], freeing the core TFIIH from 
MAT1. In the structures of free TFIIH and of the PIC-TFIIH, MAT1 acts as 
a brace to separate XPB and XPD (Fig. 3) [39,42,44]. XPD can move, 
such that the XPA pin is ideally positioned and the damage-containing 
ssDNA is immediately bound by the strongest DNA binding interface 
on XPD [41]. 3) XPA traps the dsDNA in the XPB DNA binding groove 
and shifts p8 and XPD, promoting DNA-dependent ATPase activity [41, 
60,74,85]. Although elements of this mechanism are common with XPA 
in mechanism 1 (preventing rotation and fixing XPA to TFIIH), the 
critical difference is the strand-separation pin. Could the XPC opened 
dsDNA be sufficiently large for insertion of the XPA strand separation 
pin, Trp175, negating the initial need for negative supercoiling in 
Mechanism 1? Further mutagenesis and biochemistry studies are needed 
to parse out the relative contributions of mechanisms 1 and 2 for NER. 
4. How does XPD open up the DNA? 
In contrast to XPB binding to dsDNA, XPD binds ssDNA. As expected, 
the primary ssDNA path goes along the two XPD domains HD1 and HD2. 
Two important structures of the ssDNA-bound E. coli XPD ortholog 
DinG, with and without an ATP mimetic (ADP-BeF) shed light on the 
XPD helicase mechanism (Fig. 6A) [86]. HD1 and HD2 shift from being 
apart in the resting state (ssDNA bound, but no nt cofactor) to being 
closer together in the active state with an ATP-mimetic bound. Besides 
the interactions identified by Cheng and Wigley, we examined B-factors 
in the ssDNA bound by DinG; B-factors reflect the positional stability of 
each atom and provide an indirect, but quantitative measurement of 
binding stability (Fig. 6B and C), as shown for antibody-protein in-
teractions [87]. Here the lower the B-factor, the more stabilized is the 
ssDNA. The resting DinG structure (without nt cofactor) appears to have 
tighter interaction at the 3′ and 5′ ends of the ssDNA, while the ATP 
mimetic-bound DinG has tighter interactions in the center, a region on 
HD2 near HD1. Strikingly, this central ssDNA region in the human 
TFIIH-XPA-DNA structure is lifted off from the bottom of the DNA 
binding groove [41], analogous to the DinG resting state. We define 
three changing ssDNA interaction points: HD1, HD2 Center, and 5′-HD2 
based on their associated domain and relative position to 5′ and 3′ ends 
of the ssDNA. 
We propose a multi-step model for XPD helicase activity, building on 
both the XPD structures and the Cheng and Wigley DinG insights [86] 
(Fig. 6D). 1) HD1 and 5′-HD2 bind to the ssDNA, with HD2 Center 
loosely bound, as observed in the DinG resting state. 2) ATP binding 
induces HD1 to bind the 3′ ssDNA end, shifting toward HD2 and moving 
the DNA 1 nt towards the 5′ end, as expected for a 5′–3′ translocase. 
5′-HD2 releases its hold on the DNA; if it did not, then the central ssDNA 
Fig. 5. Envisioning how XPB as a translocases negatively supercoils DNA to unwind it. Cartoons of XPB translocase, represented as a unicycle riding in the 
minor groove of dsDNA. TFIIH is represented in blue, red (XPD),magenta (XPB) and tan (MAT1). (A) In transcription initiation, TFIIE and MAT1-based girded 
protein-to-protein connection locks XPB to Pol II. With Pol II and other transcription factors gripping the dsDNA, XPB translocates in the minor groove, compels the 
dsDNA to spiral right-handed towards Pol II, induces negative supercoiling, and opens the promoter element. (B) In early stage NER, XPC-RAD23B, and XPA could fix 
the dsDNA relative to XPB. Insets) XPC-RAD23B binds dsDNA 3′ to the lesion (X) and the two bases opposite to lesion. XPA both” braces” the ssDNA against XPB and 
contributes a pin (Trp175) that helps separate the strands. XPC-RAD23B and/or XPA prevents rotation as XPB translocates in the minor groove. The DNA spirals 
towards XPC-RAD23B becomes negatively supercoiled and unwinds. Later, XPD captures the newly formed ssDNA, and XPG the dsDNA, in place of XPC. 
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would bend upward even more. 3) HD2 Center clamps down (preventing 
the ssDNA from moving back). 4) HD1 releases its hold on the ssDNA, as 
seen in DinG with ATP-mimetic bound. 5) ATP is hydrolyzed and 
released as ADP. HD1, not binding tightly to the ssDNA, shifts back to-
wards the 3′ end. 6) HD1 and 5′-HD2 clamp down on the ssDNA. 7) HD2 
Center releases the ssDNA, setting the protein back to the resting DinG 
state (Return to step 1). This multi-step process is likely regulated by 
conformational changes induced by binding of ATP, ATP hydrolysis, 
phosphate group release, and nt cofactor release and within TFIIH, 
through interactions with XPB and other TFIIH subunits. 
5. How is ssDNA loaded onto XPD? 
The strongest ssDNA binding interface of XPD is at the 5′-HD2 end. 
This is reflected in the binding to this region observed in the first XPD- 
DNA structures and by the severe impact of mutations in the 5′-HD2 
region [57,86,88,89]. We hypothesize that it is not coincidental that the 
XPA “strand separation pin” is located next to the 5′-HD2, the strongest 
ssDNA binding region on XPD. Thus, the 5′-HD2 is the most likely 
candidate for initial loading of ssDNA, opened first by XPC and then 
enlarged by XPA and XPB. This ssDNA binding is likely to occur in the nt 
cofactor-free form, which showed the strongest DNA binding at the 5′
HD2, based on low B-factor in DinG. Furthermore, a corollary to above 
helicase model is that XPD will not function as a helicase until HD1 also 
binds to ssDNA: this sets a minimal 10− 11 nt ssDNA length for XPD 
helicase action, the number of nts required to span 5′-HD2 to HD1. 
The TFIIH-XPA-DNA and DinG structures revealed the 3′ end 
threading between the HD1, Arch, and FeS domains. However, ssDNA in 
an NER reaction is always in the context of a DNA bubble with no free 
end and therefore would need to be slotted through. The DinG structures 
show just such a slot formed by opening up a 10–15 Å gap between the 
FeS and Arch domains in the structure with ATP mimetic bound 
(Fig. 6A). The center clamp of DNA (lowest B-factor) by HD2 in the ATP- 
bound state may be a grip point to facilitate slotting through of the 3′
end. In both DinG structures, the FeS domain has the highest B-factor, 
suggesting the greatest flexibility. 
6. How does XPD detect the lesion? 
Evidence that XPD detected lesions came first from yeast studies and 
later with purified proteins that showed XPD helicase and ATPase ac-
tivities are inhibited by lesions [60,62,90,91]. Archaeal XPD structures 
suggested how a lesion could be sterically blocked and thereby detected 
via a small opening in the protein at the end of a potential ssDNA binding 
groove [57–59]. 
In our mechanistic perspective, we first consider the substrate na-
ture. The typical DNA lesions repaired by NER are helix distorting and 
bulky. XPD binds ssDNA so helix distortion is not relevant, but the bulky 
size of adducts would be detectable. Based on XPD structures, two re-
gions could potentially detect different types of lesions (Fig. 7). In site A, 
first proposed in the initial XPD structures [57–59], a 
sequence-conserved narrow passage is formed by the HD1, FeS, and 
Arch domains. Site A is 7 Å at its most narrow. Lesions may be detected 
when the ssDNA moves 3′ concurrent with the DNA-unbound HD1 shift, 
Fig. 6. DinG structures reveal structural el-
ements underlying XPD helicase mecha-
nisms, lesion scanning, ssDNA loading, and 
preference against RNA. (A) Ribbon repre-
sentations of Apo and ADP-BeF-bound DinG 
structures show changes in domain organiza-
tion and flexibility. Cartoon width is based on 
B-factor, an indicator of flexibility. DinG is 
colored by domain; ssDNA backbone, by B-fac-
tor. The ssDNA is also depicted as sticks, with nt 
7 colored light orange for register. ADP-BeF and 
[4Fe-4S] are shown as spheres. (B) DNA, FeS, 
ADP-BeF, and proline in same perspective as A. 
(C) Plot of B-factor against the ssDNA nt reflects 
indirectly ssDNA stability. (D) Hypothesized 
HD1/HD2 multi-step mechanism for 5′–3′ heli-
case and lesion scanning. Overlay of domain 
boxes on ssDNA (sticks) represents tighter 
binding. Stacked DNA bases are drawn vertical.   
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after ATP hydrolysis (step 5, Fig. 6D). 
In site B, the ssDNA enters XPD as base stacked, but becomes dis-
torted as it passes over a proline (P) motif, identified in DinG structures. 
The P motif is not sequence-conserved but is structurally conserved from 
bacteria to humans. Lesions that cause one or more nts to become rigid 
might be detected by their inability to pass over the P motif when the 
HD1-bound ssDNA moves 5′ upon ATP binding (step 2). Adding an 
additional measure to force the break in base stacking, the nt bound just 
3′ to the P motif (colored light orange in Fig. 6) is the most stabilized in 
the DinG-bound ssDNA. Intriguingly, this nt is the one lifted up from the 
bottom of the DNA binding groove and may also be a contact point for 
p62 in the human TFIIH-XPA-DNA, based on unassigned density in the 
cryo-EM structure that is consistent with p62 also being involved in 
lesion detection [66]. With site B being 7 Å at its most narrow, XPD may 
use the ability of the ssDNA to maneuver between the HD2 center clamp 
and the P motif to scan for lesions that cannot, such as intra-strand 
cyclobutane pyrimidine dimer (CPD) or 6− 4 pyrimidine-pyrimidone 
(6− 4 PP) [86]. Indeed, it has been proposed that this P motif might 
sense the sugar hydroxyl in a ribonucleotide, shown to be an NER sub-
strate [86,92]. Both site A and site B would require ATP-driven 
conformational shifts between HD1 and HD2, as biochemically 
required for lesion scanning [93]. 
There is experimental support for site A over site B, for scanning 
lesions. If XPD binds the ssDNA at the ss/dsDNA junction 5′ to the lesion, 
as seen in the most recent TFIIH structure in complex with XPA [41], 
there should be ~11 nt for Site A or 6 nt for Site B of ssDNA 5′ to the 
junction. Studies to detect opened ssDNA in extracts or with recon-
stituted NER reactions show KMnO4 labeling 10− 11 nt on the 5′ side of 
cisplatin (cisPt) DNA lesion, consistent with site A detection for that 
lesion [74,94]. Comparison of the structurally implied nt number on the 
3′ side of the lesion to the KMnO4 data is complicated by the likelihood 
that the ss/dsDNA junction is not directly binding XPD but rather is 
bound by the XPG nuclease. XPG, which makes the second cut in NER 
but binds before ERCC1/XPF, is a founding member of the FEN1/XPG 5′
nuclease superfamily that binds and sculpts ss/dsDNA junctions [31, 
95–100]. Yet, unlike the flap endonuclease FEN1, which must thread a 
DNA end to avoid genome instability [101], XPG can cut bubble DNA, so 
it must be able to slot ssDNA into its active site when bound to the 
ss/dsDNA [102]. Perhaps the strongest support for site A (and not site B) 
being critical for lesion detection comes from the finding that mutation 
of site A residues reduces CPD excision [63]. These considerations do not 
however exclude the possibility that site B may contribute to or even be 
required for less obvious DNA damage. 
7. Where is XPC-RAD23B relative to TFIIH? 
If XPD is scanning for lesions and site A is on the 3′ side of XPD, the 
lesion should start out on the 3′ side of XPD before scanning initiates. 
However, is this where XPC-RAD23B starts when it first recruits TFIIH? 
Before TFIIH, XPC-RAD23B, as the major protein initially detecting le-
sions, will have recognized the lesion by flipping out the undamaged 
DNA opposite to the lesion but will be primarily bound to the dsDNA 3 
nts 3′ upstream from the lesion (Fig. 5B) [65,72]. XPC-RAD23B then 
recruits TFIIH to the damage site, but it is not known where the 
XPC-RAD23B-bound lesion is positioned relative to XPB and XPD. The 
pH domain in p62 that interacts with XPC is not modeled in any TFIIH 
models, and thus its position cannot decipher the relative XPC position. 
However, we postulate two possible locations. In model 1, XPC-RAD23B 
starts off on the 3′ side relative to XPD and as XPD scans for the lesion 
5′–3′, the lesion must also be on the 3′ side relative to XPD (and XPB). 
Translocation by XPB would then open up the DNA 5′ to the lesion 
enabling concurrent ssDNA binding by XPD. In model 2, XPC-RAD23B 
starts off near the XPB and XPD interface. It incorporates the fact that 
as XPB is translocating, the dsDNA is moving 5′–3′ (based on XPB and 
the lesion-containing strand). A rough calculation based on the Pol II 
promoter opening indicates that XPB needs to translocate the same 
number of base pairs as the number of promoter nts that are opened up. 
By analogy to ~11 nts of ssDNA bound in the XPD/DinG structures, XPB 
would translocate ~11 base pairs. This movement would place the 
lesion, after XPB translocation, on the 3′ side of XPD. If the lesion started 
on the 3′ side as in model 1, then the XPB translocation would move the 
lesion even farther 3′ and XPD would need to make up for the gap. 
8. What is the purpose of the [4Fe-4S] cluster in XPD? 
XPD ranks among an elite group of replication and repair proteins 
that contain unique [4Fe-4S] cluster co-factors (including DNA poly-
merases, helicases, nucleases, primases, and glycosylases), as reviewed 
in [3]. There should be a selective advantage to having a [4Fe-4S] 
cluster, yet it is unclear what common advantage it might be other 
than structural integrity or in folding. There are many disadvantages. 
[4Fe-4S] clusters have multiple oxidation states, are sensitive to oxygen 
and cell stress, and are potentially toxic and mutagenic. They are 
metabolically expensive, requiring a specialized set of proteins for their 
assembly and incorporation in proteins. Why are electron-rich [4Fe-4S] 
clusters conserved in essential proteins that are so close to 
oxidation-sensitive DNA? One provocative hypothesis is that [4Fe-4S] 
clusters provide a signaling mechanism that uses charge transfer 
through duplex DNA. In the absence of mismatch or DNA damage that 
disrupts base stacking, electrons can travel over hundreds of base pairs 
[103–105]. Thus, effective charge transfer through the DNA would 
signal the absence of damage. Reduction of the [4Fe-4S] cluster in XPD 
reduces DNA binding [106,107]. Hence, if an electron is sent from a 
gap-filling DNA polymerase to XPD in TFIIH, which is only possible after 
creation of full duplex, it would serve as a signal that synthesis is 
completed and promote release from the DNA. Indeed, it is perhaps 
significant that lesion-scanning site A borders the [4Fe-4S] cluster and 
that one of the site A residues, Tyr192, bridges DNA and the [4Fe-4S] 
cluster. Although the DNA in this region is ssDNA, the bases are 
Fig. 7. Implicated Lesion Scanning Sites in XPD. Along the ssDNA binding 
path on XPD, there are two sites which would sterically clash the CPDs. Ribbon 
representation of human XPD with DNA, based on TFIIH-XPA-DNA structure 
with overlaid CPD (stick) at the putative lesion-detecting sites. Parts of XPD 
were removed by depth slicing for clarity. For register, the nt corresponding to 
nt #7 in Fig. 6 is colored light orange. Otherwise, the DNA is colored as in 
Fig. 3. Insets show Sites A and B, with CPD steric clashes (blue lines). 
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stacked from the 3′ side, perhaps indicating directionality of the signal. 
Mutation of this residue abrogated the ability of TFIIH to scan for CPD 
lesions, which was attributed to widening site A [63]. It would be 
interesting to test if this mutation also interfered with the charge 
transfer between the cluster and DNA. Another provocative hypothesis is 
that the [4Fe-4S] aid in opening of the DNA, as this is a common function 
between polymerases, helicases, primase, and glycosylases. However, 
how [4Fe-4S] would do this is unclear. 
9. The paradox of TFIIH in transcription initiation and NER 
Evolution teaches us fundamental relationships about the cell 
biology of transcription initiation and repair. So, in thinking about TFIIH 
mechanisms, is it worth considering which of its roles came first? That 
TFIIH acts in both transcription initiation and NER seems paradoxical 
when viewed in terms of the differences in these processes, their distinct 
requirements, and the risks of combining their disparate activities. Why 
would TFIIH include a second SF2 helicase family enzyme XPD that is 
not required for transcription initiation and that adds an XPD [4Fe-4S] 
vulnerability to the transcription initiation process? Did a role for 
TFIIH in NER or transcription initiation come first? Transcription initi-
ation is understood to be a more essential role. Or is it? 
A key insight comes with the observation that the biggest block to 
replication (and thus to life) is transcription. The Merrikh lab used single 
molecule techniques to show in bacteria that only one of two potential 
replisomes was active in each cell at any one time during replication 
[108]. Only when transcription was inhibited were two active repli-
somes detected, suggesting that transcription caused the major block to 
replication. This dramatic blocking of the replisome was not due to DNA 
breaks, aberrant resolution of topological strain, or other DNA damages 
blocking the DNA polymerase per se, i.e. it is transcription that is the 
major block to replication. An important caveat to this argument is that 
TCR proteins are not essential. Given that this field is still making 
important discoveries, we speculate that removal of the RNA polymerase 
is so important, that the cell has developed multiple ways to compensate 
for loss of any one pathway. 
If collision with transcription is the major replication block, then 
resolution of this collision between the RNA polymerase and the repli-
cation machinery must be the second most critical process after repli-
cation. As RNA polymerase stalled at a lesion and RNA polymerase that 
collided with the replication machinery have common logistical issues, 
could a version of TCR have been initially involved? Thus, transcription 
initiation and global DNA repair, albeit essential, could be a secondary 
evolutionary pressure on TFIIH. This sweeping line of thought may seem 
at first fanciful, overly simplistic, and impossible to prove, but it serves a 
purpose. When considering TFIIH mechanisms, it might be productive to 
consider TCR as the possible original process that has been subsequently 
adapted for transcription initiation and global NER. In other words, the 
answer to whether the chicken or the egg came first might be neither in 
the case of TFIIH. TC-NER may be central to truly understanding TFIIH, 
underscoring the value of further research on this possible progenitor 
pathway. 
There are certain key observations consistent with the TC-NER pro-
genitor idea. First, XPB translocase activity in TFIIH is not required for 
all promoter openings [48], suggesting that it is not essential per se and 
that TFIIH could have been added to improve efficiency. Second, the 
~25 nt oligonucleotide released by XPF-ERCC1 and XPG in NER re-
sembles the amount of DNA covered by an elongating Pol II (Fig. 8) 
[109]. Indeed, the relative lesion position in NER is similar [110]. In 
NER, the lesion is positioned in an ~25mer nt DNA bubble, with 5 nt of 
ssDNA 3′ to the lesion and ~20 nt 5′ to the lesion. In the case of a lesion 
at the Pol II active site, Pol II covers 7–8 nt on the 3′ side and 15 nt on the 
5′ side. These numbers do not exactly match and must additionally take 
into account XPG and XPF-ERCC1 incision into the dsDNA, yet the 
similarity is striking. Third, the strand that would contain the 
NER-repaired lesion in the TFIIH-XPA-DNA complex has more 
interactions with XPB and is the same strand that is being transcribed 
and would block the polymerase if it contained a lesion (Fig. 2, black 
strand). Fourth, based on TFIIH-related diseases, Cockayne syndrome 
(CS), characterized by inability to resume RNA synthesis after DNA 
damage and, as such, defective TCR, has a far worse phenotype than 
xeroderma pigmentosum, caused by defective GG-NER. 
Taking this model further, if TFIIH activity initially developed for 
TCR, then one would want to remove a trapped and replication-blocking 
Pol II from the DNA. If the dsDNA on either side of the trapped Pol II is 
cut, this would cause a dsDNA break, toxic or lethal at worse, mutagenic 
at best. It would be less toxic to make ssDNA breaks on either side. 
However, Pol II is clamped down on the dsDNA portions. If Pol II was 
altered such that it clamped on only one strand, removal of this one ss 
section would allow DNA polymerase to simply patch the removed 
section. To do this, it would be important to increase the elongating 
transcription bubble such that Pol II was covering only ssDNA and the 
blocking Pol II could be released, still clinging onto the damaged DNA 
strand (black in Fig. 8A schematic). Conversely, this hypothesis would 
explain why these lesions are removed as such large oligonucleotides 
during NER. How could one generate ssDNA the length of Pol II? The 
Fig. 8. DNA covered by Pol II resembles an NER incision product in size 
and positioning relative to a transcription-blocking lesion. (A) The DNA on 
the transcribing strand covered by an elongating Pol II. The top 2 views show 
yeast Pol II (surface representation) with RNA (green) and DNA (orange, black) 
or just the RNA-DNA (different orientations). The transcribing-strand region 
covered by Pol II is colored black. The bottom view is a schematic of the RNA/ 
DNA. The cisPt position (red) is based on the Pol II structure with cisPt (2R7Z. 
pdb). (B) Schematic NER DNA bubble with a cisPt lesion. The oligonucleotide 
released in NER is marked in black. Figure adapted from Evans, 1997. The DNA 
bubble position is based on the relative dsDNA incision positioning of XPF 
and XPG. 
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answer is TFIIH. 
How does TFIIH work during TCR? That is an open question, as TCR 
has never been reconstituted in vitro. An “Occam’s razor” model is that 
Pol II is removed by ubiquitination and proteolysis [32,33], and TFIIH 
acts as it does in global NER. The pH domain of p62 that interacts with 
XPC also interacts with UVSSA in TC-NER, providing a possible unified 
mechanism between TC-NER and GG-NER for the engagement of TFIIH 
[36]. However, TFIIH is large enough such that XPB and XPD could 
access the DNA on either side of an elongating Pol II. This would require 
changes in XPB and XPD positioning, as well as changes in DNA 
compared to the Pol II PIC complex. Perhaps XPD is binding the ssDNA 
in an R-loop? Although proteins involved in TCR are known, their 
mechanism of action remains unknown. Nonetheless, such a model 
suggests an intriguing origin for NER. 
10. What does the location of TFIIH disease mutations tell us 
about TFIIH functions? 
Although the three major TFIIH diseases have discrete phenotypes, 
all are autosomal recessive and associated with sun sensitivity [111]. 
Xeroderma pigmentosum (XP) patients have 1000-fold increase in skin 
cancers; XP cells are defective for NER. XP/CS patients with mutations in 
NER proteins show severe neurological and developmental abnormal-
ities, but with no increase in cancer risk. XP/CS cells are defective for 
both NER, TC-NER, and resumption of RNA synthesis after UV damage. 
In contrast to XP and CS, trichothiodystrophy (TTD) patients show 
symptoms of brittle hair and nails, intellectual impairment, decreased 
fertility, shorter life span and short stature with no increased risk of 
cancer [112]. 
Sequencing of TFIIH patient DNA and careful identification of 
disease missense mutations provide a powerful means to view the 
structure-function relationships of XPB, XPD, and p8. Unlike XPG dis-
ease mutations [100], each disease mutation in TFIIH cannot destroy the 
protein integrity or essential transcription initiation functions of TFIIH. 
Yet, there are serious disease phenotypes, it must disrupt one or more of 
the TFIIH functions. Notably disease-causing mutations center on XPD. 
There are 31 disease missense mutations in XPD, two in XPB, and one in 
p8 [113–125]. Four mutations have XP and TTD overlapping pheno-
types, suggesting impact on multiple TFIIH functions. Understanding of 
how these mutants mis-function is informed by interpreting them in the 
context of TFIIH structures: indeed, the insights obtained have been 
increasingly informative as larger structures of complexes are deter-
mined [43,55,57]. 
Interestingly, most patient mutations map to secondary structure 
ends or loops, highlighting the significance of these positions. Whereas 
half the TTD mutations fall within helices, this is rare for XP and XP/CS 
mutations. Strikingly, 80 % of disease mutations localize to XPD helicase 
domains with none in transcription initiation-essential XPB translocase 
domains. Analysis of individual mutations can be found in our recently 
reported modeling and computational analysis of TFIIH [43]. 
In general, we find that disease mutations do not cluster by disease in 
the primary sequence or spatially in the structure (Fig. 9). However, they 
do fall into general structural categories. 1) The 13 TTD and 4 XP/TTD 
mutations map to protein-protein interfaces or interfacial helices in p8, 
XPB and XPD, suggesting that TTD mutations disrupt protein-protein 
interfaces (directly or through breaks in helices at interfaces). TTD 
mutations thus would weaken assembly of TFIIH subunits while 
retaining residual XPB translocase activity for essential transcription 
initiation function, consistent with the model that TTD partially disrupts 
TFIIH transcription initiation, resulting in segmental aging phenotypes. 
Fig. 9. TFIIH disease mutations mapped onto TFIIH-XPA- 
DNA. A) Positions of XP, CS, and TTD disease mutations 
(spheres) are shown on NER TFIIH-XPA-DNA structure. Each 
protein or subunit are colored as in Fig. 3, except XPD is 
colored by domain. Note that p62 was not modeled in this 
structure. B,C,D) Zooms highlight general features of each type 
of disease mutation. Most XP mutations are at XPD DNA or 
ATP-binding sites. Most CS mutations are at allosteric regions 
that change conformation. Most TTD mutations are at protein- 
protein interfaces. B and D are in same perspective as A. C is 
oriented to highlight HD1 (blue) and HD2 (moss green) inter-
face. Parts of XPD were removed by depth slicing for clarity.   
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2) All 14 XP and XP/TTD mutations map to XPD. Surprisingly no XP 
mutations map to XPB, suggesting either a minor role in NER or it is 
difficult or impossible to separate XPB function in repair (e.g. ATPase) 
from that in transcription initiation. XP mutations tend to fall into po-
sitions near the ssDNA or ATP-binding regions of XPD, indicating a 
direct impact of XPD helicase-relevant functions. The remaining set of 
XP mutations map close to XPB, p44, and p62, suggesting that these 
interfaces are important for NER. 3) The seven XP/CS mutations in XPD 
or XPB map into regions implicated in allosteric communication be-
tween TFIIH dynamic communities [43]. We have defined communities 
as groups of residues that move together in our molecular dynamics 
analysis, analogous to a machine gear. Superseding the traditional 
separation of TFIIH by subunit, parts of a subunit polypeptide can 
belong to different communities, and one community can be composed 
of parts from multiple subunits. Thus, the location of XP/CS mutations in 
these communities point to allosteric changes in TFIIH as being critical 
for TCR. Interestingly, five of seven XP/CS mutations are close to p62, 
which spans communities and bridges the XPD ssDNA binding path, the 
XPD ATP binding site, and TFIIE. Although p62 has been difficult to 
model because of its molecular rigging-like structure, these XP/CS mu-
tations support a critical role for p62. 
11. How may TFIIH mechanisms impact cancer mutational 
signatures and biomarkers for therapy? 
Mutational signatures are characteristic combinations of mutation 
types arising from specific mutagenesis processes such as defective NER. 
For precision cancer therapy, biomarkers can predict which patients will 
have the highest likelihood of responding to selected therapies such as 
DNA damaging agents or have adverse side effects with particular 
therapies as well as determine patient prognosis. TFIIH as a target for 
cancer therapeutics is under active investigation with inhibitor efforts 
targeting the kinase module or XPB (reviewed in [126]); however, there 
are as yet no TFIIH inhibitors in the clinic. 
Is it possible to exploit genetic or functional repair defects in TFIIH 
through synthetic lethal mechanisms, as has been done for other DNA 
damage response proteins? Notably, Poly(ADP-ribose)ylation (PAR-
ylation) by PAR polymerase 1 (PARP1) and PARylation removal by poly 
(ADP-ribose) glycohydrolase (PARG) critically regulate DNA damage 
responses, so PARP1 inhibitors and PARG inhibitors are synthetic lethal 
with BRCA1, BRCA2, or other genes in the Fanconi anemia/BRCA 
pathway that cause defects in homologous recombination repair (HRR) 
[127,128]. In fact, PARylation and NER are linked at two stages. First, 
UV-DDB-associated PARP1 PARylates chromatin DNA and DDB2 at sites 
of UV damage [129]. Second, PARP1-mediated PARylation promotes 
XPC localization at DNA lesions, and XPA binds PAR chains [130–132]. 
Intriguingly, this link may extend to CS disease phenotypes: reduced 
NAD + levels, a result of excess PARylation that can cause cell death via 
the allosteric activation of Apoptosis-Inducing Factor [133], are asso-
ciated with key CS phenotypes, and these phenotypes can be reduced in 
a mouse model system by NAD + supplementation [134,135]. 
In any case, these NER links to PARylation, where signatures and 
biomarkers were key to therapeutic success, highlight the question: can 
mutational signatures and biomarkers for NER be used as tools to guide 
precision therapies and clinical trials [136]? For example, ERCC2/XPD 
mutations in urothelial cancers show an increase in mutations attributed 
to COSMIC signature 5, a mutational signature characterized by a broad 
spectrum of base changes [137]. NER-deficient tissues also show 
increased Signature 8 mutations (increased double nucleotide sub-
stitutions), which may help predict NER-deficiency [138]. 
Importantly, mutational signatures are jointly shaped by DNA 
damage and DNA repair. NER prevents up to 99 % of missense muta-
tions, almost uniformly across the mutation spectrum [139]. Investi-
gating changes in UV mutation signature between adult skin tumors and 
those from XPC defective XP patients, showed a 30-fold increase in 
mutation rate per year in XP patients across all types of base 
substitutions. Yet, there was also a context dependent shift, with ~3 
times more mutations acquired in NpCpT (N = A/G/T/C) and TpCpD 
contexts (D = A/G/T). As XPC deficiency inactivates GG-NER, the 
observed shift may reflect the loss of GG-NER efficiency despite 
compensation by TC-NER, which merits further study. Moreover, such 
NER defects may offer actionable knowledge for therapies and clinical 
trials. For example, a recent landmark study showed that XPD/ERCC2 
helicase mutations that cause NER defects predict cisplatin efficacy for 
bladder cancer [140]. We therefore anticipate that the structural 
mechanisms considered here may shed light on mutations or poly-
morphisms likely to both cause repair defects and inform possible 
mutational signatures and biomarkers. 
12. Perspective and unanswered questions 
With its features and multi-functionality, TFIIH provides key insights 
and opportunities to learn about a quintessential macromolecular ma-
chine. By going beyond the molecular roles of TFIIH and its functional 
partners in DNA repair and transcription initiation, we examine how the 
composite proteins and the assembled TFIIH machine accomplish their 
activities. Building upon the field’s current knowledge and ideas, we 
considered possible mechanisms for how XPB translocation leads to 
DNA opening through negative supercoiling; how XPA contributes to 
XPB unwinding with a helicase strand-separation pin; how ATP-binding, 
hydrolysis and release in XPD enables ssDNA movement and ssDNA 
loading, and how XPD uses sterically narrow channels to find and po-
sition lesions. We also examined insights learned from human disease 
mutations that currently teach us the fundamental biology that may be a 
necessary precursor to enable translational efforts to help these patents 
in the near term. 
The detailed structural mechanisms that underlie TFIIH function are 
commensurate with the complexity of its functions in transcription 
initiation, NER, and TCR. Our analyses suggest that the continued 
combination of structures of TFIIH with different proteins, DNA sub-
strates, and nucleotide states, biochemical experiments, cell biology, 
computational analyses and disease mutations will successfully tease 
apart the interwoven and step-wise coordination of these three pro-
cesses. Notably, many questions remain including how TFIIH subunits 
are coordinated with each other and with partner proteins in NER, TC- 
NER, and transcription-initiation. For example, the combination of 
broad substrate specificity and excision accuracy in GG-NER involves 
concerted actions of TFIIH with XPC, RPA, XPA and XPG to shape the 
bubble and pre-incision complex, but how this works is enigmatic. 
Furthermore TFIIH acts in dsDNA break-induced transcription and may 
provide a mechanism of repair pathway choice [141], so how the TFIIH 
machine acts at the heart of different transcription and repair events 
merits attention. 
Indeed, a key outstanding question is how does TFIIH control its 
nuclease activities? Incision by XPF-ERCC1 and XPG nucleases create 
the most toxic repair intermediate in NER suggesting they are both 
regulated and licensed, as is MRE11 nuclease for homology directed 
repair of dsDNA breaks [142]. Elegant Wood laboratory radiographs of 
NER DNA products show precise 26 nt excisions when the lesion is 
induced by Pt [143] suggesting incision is regulated and licensed when 
XPB and XPD have fully opened the NER bubble. Does such licensing and 
regulation come from a specific number of open nts, changes in the DNA 
conformation, blocked ATP hydrolysis or ATP/ADP exchange when a 
bulky lesion stuck at XPD site A or site B stalls XPD, how RPA is bound, 
or something else? Currently molecular dynamics analyses point to XPD 
at the center of TFIIH networked molecular communities, as best posi-
tioned to access the damage and mediate licensing of NER incisions [43]. 
In fact, we are struck by the occurrence once again of disrupted base 
unstacking in the DinG structures and predict that this will be a central 
mechanism for lesion sensing, as first proposed and observed for UvrB 
[144–146] and observed for uracil-DNA glycosylase lesion recognition 
and removal [147]. Moreover, the observed key roles of flexibility and 
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conformational change in NER suggest that experiments to define both 
flexibility and functional conformations in solution under near physio-
logical conditions will be critically important to build upon the foun-
dational cryo-EM structures, and we expect X-ray scattering will be a 
compelling method for such efforts [148]. Overall, we anticipate that 
the insights, ideas, and questions regarding TFIIH structure–activity 
relationships presented here may aid and focus ongoing experiments 
and research relating to both biology and medicine. 
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